Bioglan Pharma
Article Abstract:
Bioglan Pharma is a specialist pharmaceutical company that should benefit from its acquisition of Hexal's skincare division.
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Bioglan Pharma PLC
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
Fulcrum Pharma
Article Abstract:
The performance of Fulcrum Pharma is examined, and the company's strengths include a strong Japanese presence.
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
Fulcrum Pharma
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
SR Pharma
Article Abstract:
SR Pharma has an increasing number of licensing agreements, though the company's cash pile is limited.
Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
SR Pharma
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: Management, Pharmaceutical industry, Drugs
Similar abstracts:
- Abstracts: Cantab Pharmaceuticals. Merck and Co
- Abstracts: A wooly area. Roche. KS Biomedix
- Abstracts: The way ahead. Volume control. Stop, look, listen
- Abstracts: Domestic bond markets. Clearing the paper trail. The year of Asian domestic bonds
- Abstracts: Drugs in crops-the unpalatable truth. China pushes liver proteomics. Pharmacogenetics and the practice of medicine
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.